Phase 3 Readout~month

Phase 3 Topline: A Randomized, Double-blind, 3-Arm Parallel Design Study to Investigate the Efficacy, Safety, Tolerab

Name: Phase 3 Topline: A Randomized, Double-blind, 3-Arm Parallel Design Study to Investigate the Efficacy, Safety, Tolerab
Start: 2027-12-31

December 31, 2027

Company: Centessa Pharmaceuticals plc (CNTA)
Drug: placebo
Indication: Narcolepsy Type 1; Narcolepsy Type 2

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start Free Full Calendar

Phase 3 Topline: A Randomized, Double-blind, 3-Arm Parallel Design Study to Investigate the Efficacy, Safety, Tolerab — CNTA Phase 3 Readout | BioSniper